CMPX COMPASS THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, COMPASS THERAPEUTICS INC reported revenue of n/a, net income of −$25.2M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was $0, down 100.0% on the year before.
CMPX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$72.8M, net income −$66.5M (margin n/a), EPS n/a
- Fiscal year ended Dec 2024: revenue $850K, gross profit n/a, operating income −$56.6M, net income −$49.4M (margin -5808.8%), EPS n/a
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$50.4M, net income −$42.5M (margin n/a), EPS n/a
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$41.7M, net income −$39.2M (margin n/a), EPS n/a
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$81.9M, net income −$82.2M (margin n/a), EPS −$1.31
CMPX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$25.2M, EPS n/a
- Quarter ended Mar 31, 2026: revenue n/a, net income −$18.3M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$15.7M, EPS n/a
- Quarter ended Sep 30, 2025: revenue $0, net income −$14.3M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $0 (down 100.0% year over year), net income −$19.9M, EPS n/a
- Quarter ended Mar 31, 2025: revenue n/a, net income −$16.6M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$15.0M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $0, net income −$10.5M, EPS n/a
- Quarter ended Jun 30, 2024: revenue $850K, net income −$13.1M, EPS n/a
- Quarter ended Mar 31, 2024: revenue n/a, net income −$10.8M, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$13.4M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $0, net income −$9.96M, EPS n/a
- Quarter ended Jun 30, 2023: revenue $0, net income −$11.3M, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$7.84M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$11.6M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$12.0M, EPS n/a
- Quarter ended Jun 30, 2022: revenue n/a, net income −$8.49M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$7.16M, EPS −$0.07
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$13.0M, EPS $0.00
- Quarter ended Sep 30, 2021: revenue n/a, net income −$5.98M, EPS −$0.10
CMPX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$49.1M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$44.9M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$40.6M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$34.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$19.7M, share buybacks n/a
CMPX balance sheet
- Jun 30, 2026: cash $35.5M, total assets $190M, total liabilities $24.1M, shareholders' equity $166M
- Mar 31, 2026: cash $55.2M, total assets $205M, total liabilities $18.7M, shareholders' equity $186M
- Dec 31, 2025: cash $30.6M, total assets $220M, total liabilities $22.8M, shareholders' equity $197M
- Sep 30, 2025: cash $46.2M, total assets $231M, total liabilities $21.6M, shareholders' equity $210M
- Jun 30, 2025: cash $22.9M, total assets $117M, total liabilities $23.5M, shareholders' equity $93.2M
- Mar 31, 2025: cash $41.0M, total assets $131M, total liabilities $21.2M, shareholders' equity $110M
- Dec 31, 2024: cash $43.5M, total assets $140M, total liabilities $15.2M, shareholders' equity $125M
- Sep 30, 2024: cash $19.4M, total assets $149M, total liabilities $10.8M, shareholders' equity $138M
What is CMPX's revenue?
COMPASS THERAPEUTICS INC reported $0 of revenue for the fiscal year ended December 2025.
Is CMPX profitable?
No. COMPASS THERAPEUTICS INC lost $73.4M over the last four quarters.